P-77: Protective Role of GnRH Antagonist (Cetrorelix) on Side Effect of Vincristine on Diameter of Seminiferous Tubules of Mice

Background: Infertility problem affects young couples. One of the known causes of spermatogenic disorder is chemotherapy in patients with cancer. Since dividing cells are mainly affected by anticancer drugs, the aim of the present study is to investigate the preventive effect of GnRH antagonist on spermatogenic defect produced by anticancer drug. Materials and Methods: In the present study 30 adult male mice aging 6-8 weeks were used. The mice were divided into 3 equal groups as: control, vincristine (V) group and vincristine + cetrorelix, (V+C) group. A single dose of Vincristine was injected as ip, at 1.5 mg/kg. In (V+C) group cetrorelix injection was started one week before vincristine treatment and continued for 3 more weeks. Since spermatogenic cycle in mice is 35 days, mice in all groups were sacrificed 35 days after vincristine injection and testis specimens were prepared for Light Microscopic studies. Results: LM study showed that mean diameter of seminiferous tubules was 190.16 ± 8.34 μm in control group, 135.52 ± 5.59 μm in V group and 178.27 ± 3.93 μm in V+C group. The rate spermatogonia in control group was 47.42 ± 1.96 μm, in V group was 16.53 ± 2.37 μm, and in V+C group was 36.28 ± 7.98 μm. Statistical analysis of data showed significant difference in rate diameter of somniferous tubules and spermatogonia, between control group and V group (p<0.05) and also between V group and V+C group (p<0.05) but V+C group was similar to control group. Conclusion: According to the result it is concluded that GnRH antagonist administration before cancer treatment could partially prevent the side effect of anticancer drugs.